Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.53 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22034224 | 0.93 | TYMP (0.55) | TYMPP2RY12PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL22033791 | 0.93 | TYMP (0.55) | TYMPP2RY12PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL30200670 | 0.91 | TYMP (0.56) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL6900160 | 0.91 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL1040958 | 0.91 | TYMP (0.56) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL6834984 | 0.91 | TYMP (0.56) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL6899475 | 0.90 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL23650062 | 0.90 | TYMP (0.58) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL6513309 | 0.90 | TYMP (0.58) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL30396368 | 0.90 | TYMP (0.58) | TYMPP2RY12ADORA1P2RY2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | claimed |
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6806269-B1 | EFFECTIVE AT LOWER CONCENTRATIONS; SUCH AS 6-(((1,1-DIMETHYL-ETHOXY)CARBONYL)AMINO)-5-METHYL-2-(METHYL(PHENYLMETHYL) -AMINO)-4H-3,1-BENZOXAZIN-4-ONE | G. D. SEARLE & COP | 2004-10-19 | — | — | US | disclosed |
| EP-1210088-A4 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF HERPES SIMPLEX VIRUS | SEARLE & CO (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1210088-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF HERPES SIMPLEX VIRUS | G.D. SEARLE & CO. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001003697-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF HERPES SIMPLEX VIRUS | G.D. SEARLE & CO. (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | GABBR1, GABBR2, EBNA1BP2 | TYMP 955/4885P2RY12 511/4885PRKAG1 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.